Cardiol Therapeutics Inc. (CRDL) Institutional Ownership

Ownership Summary

Cardiol Therapeutics Inc. (NASDAQ:CRDL) showed up in the 13F filings of 40 institutional investors as of December 2025.

• These investors collectively held 10.7% of Cardiol Therapeutics's outstanding shares in December 2025, up from 9.3% in September 2025.
• Their total shares held in CRDL increased 33.1% from the prior quarter, while the number of investors in Cardiol Therapeutics decreased 9.09% year over year.
• Of these 40 funds, 20 grew their exposure to Cardiol Therapeutics, 11 cut back, and 9 maintained positions.
• The aggregate institutional position in Cardiol Therapeutics amounted to 9.09Mn shares as of December 2025, up by 2.26Mn shares quarter on quarter, and up 1.36Mn shares year over year.
• As of December 31, 2025, the biggest holder of Cardiol Therapeutics is MMCAP International Inc. SPC at 15.35Mn shares, representing 18.12% of shares outstanding.
• Top purchasers of CRDL stock for the quarter ending December 2025 included MMCAP International Inc. SPC (15.14Mn), Ikarian Capital, LLC (2.72Mn), CITADEL ADVISORS LLC (819.9K), BOOTHBAY FUND MANAGEMENT, LLC (794.88K), RENAISSANCE TECHNOLOGIES LLC (229.81K).
• The largest sales of CRDL for the quarter ending December 2025 came from Goldman Sachs Group Inc (324.6K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (133.33K), Morgan Stanley (94.04K), Boyer Financial Services, Inc. (10.0K), UBS Group AG (7.94K).
• Business Quant data shows the 10 biggest positions in Cardiol Therapeutics as of December 2025 are held by MMCAP International Inc. SPC (15.35Mn), Tejara Capital Ltd (5.13Mn), Ikarian Capital, LLC (2.72Mn), CITADEL ADVISORS LLC (819.9K), BOOTHBAY FUND MANAGEMENT, LLC (794.88K), TWO SIGMA INVESTMENTS, LP (534.21K), INTEGRITY ALLIANCE, LLC. (465.02K), Goldman Sachs Group Inc (332.4K), Morgan Stanley (250.42K), RENAISSANCE TECHNOLOGIES LLC (229.81K).